Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News and Analysis
  • Published:

2011 in reflection

Nature Reviews Drug Discovery volume 11, pages 6–8 (2012)Cite this article

Subjects

A Corrigendum to this article was published on 10 February 2012

This article has been updated

Last year saw an upturn in new drug approvals, the end of patent protection for the world's top-selling drug, continued regulatory negotiations and more.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Change history

  • 10 February 2012

    Daclatasvir was originally misidentified as an NS5A protease inhibitor, when it is an NS5A replication complex inhibitor. This has been corrected in the online version of the article.

Authors
  1. Asher Mullard
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mullard, A. 2011 in reflection. Nat Rev Drug Discov 11, 6–8 (2012). https://doi.org/10.1038/nrd3643

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3643

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research